Scarica l'app Stockscreener
1.57
1.26%
-0.02
Pre-mercato:
1.53
-0.04
-2.55%
Precedente Chiudi:
$1.59
Aprire:
$1.56
Volume 24 ore:
581.55K
Relative Volume:
0.51
Capitalizzazione di mercato:
$391.07M
Reddito:
$14.56M
Utile/perdita netta:
$-63.37M
Rapporto P/E:
-5.6414
EPS:
-0.2783
Flusso di cassa netto:
$-19.44M
1 W Prestazione:
+2.61%
1M Prestazione:
-19.49%
6M Prestazione:
-8.72%
1 anno Prestazione:
+259.10%
Intervallo 1D:
$1.54
$1.605
Intervallo di 1 settimana:
$1.45
$1.63
Portata 52W:
$0.3651
$2.09
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Nome
Lineage Cell Therapeutics Inc
Settore
Industria
Telefono
510-871-4188
Indirizzo
2173 Salk Avenue, Suite 200, Carlsbad, CA
Compare LCTX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.57 | 391.07M | 14.56M | -63.37M | -19.44M | -0.2783 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-20 | Iniziato | Craig Hallum | Buy |
| 2022-11-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-14 | Iniziato | B. Riley Securities | Buy |
| 2021-08-19 | Iniziato | Noble Capital Markets | Outperform |
| 2021-03-31 | Iniziato | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Borsa (LCTX) Ultime notizie
Q4 2025 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus
Q3 2025 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus
If You Invested $1,000 in Lineage Cell The (LCTX) - stocktitan.net
Lineage Cell Therapeutics (LCTX) price target increased by 20.00% to 5.10 - MSN
Lineage Cell Therapeutics pushes scalable platforms to address drug discovery complexity - Traders Union
Lineage Cell Therapeutics, Inc. (LCTX) stock price, news, quote and history - Yahoo Finance UK
LCTX SEC FilingsLineage Cell The 10-K, 10-Q, 8-K Forms - stocktitan.net
Lineage Cell (LCTX) Launches Its Latest Cell Therapy Program - Yahoo Finance
Earnings Miss: What are the future prospects of Lineage Cell Therapeutics Inc2026 Trade Ideas & Long-Term Growth Stock Strategies - baoquankhu1.vn
Lineage Cell Therapeutics launches new CED cell therapy program - Eyes On Eyecare
10 Best Penny Stocks That Could Triple Your Money - Insider Monkey
Volume Recap: Can Lineage Cell Therapeutics Inc maintain sales growthTrade Performance Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Retail Trends: Is now the right time to enter Lineage Cell Therapeutics IncGap Up & Risk Managed Investment Signals - baoquankhu1.vn
Aug Breakouts: Is Lineage Cell Therapeutics Inc stock overvalued or fairly priced2026 Institutional Moves & Safe Entry Momentum Stock Tips - baoquankhu1.vn
LCTX Should I Buy - Intellectia AI
Defender Capital LLC. Buys Shares of 6,829,099 Lineage Cell Therapeutics, Inc. $LCTX - MarketBeat
B. Riley Financial Issues Positive Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price - MarketBeat
ETF Watch: Is Lineage Cell Therapeutics Inc a top pick in the sector2026 Review & Precise Swing Trade Entry Alerts - baoquankhu1.vn
LCTX: HC Wainwright Reiterates Buy Rating with $9 Price Target | - GuruFocus
HC Wainwright Reiterates Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) - MarketBeat
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease - BioSpace
Lineage Cell Therapeutics unveils preclinical therapy for Fuchs dystrophy and Bullous Keratopathy - Traders Union
Lineage Cell Therapeutics (LCTX) Expands with New Corneal Cell T - GuruFocus
[EFFECT] Lineage Cell Therapeutics, Inc. SEC Filing - Stock Titan
Geopolitics Watch: Can Lineage Cell Therapeutics Inc scale operations efficiently2026 Intraday Action & Verified Stock Trade Ideas - baoquankhu1.vn
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. - Benzinga
Insider Buying: Brian Culley Acquires 15,000 Shares of Lineage C - GuruFocus
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) CEO Brian Culley Purchases 15,000 Shares - MarketBeat
Lineage Cell Therapeutics (LCTX) CEO adds 15,000 shares in open-market purchase - Stock Titan
Lineage Cell Therapeutics, Inc. Files Form 8-K for At-The-Market Offering – Key Company and Security Information (LCTX, NYSEAMER) 232425 - Minichart
Lineage extends cash runway into Q2 2028 while advancing OpRegen and new pipeline programs - MSN
Lineage Cell Therapeutics files prospectus supplement for up to $60 million share offering - Investing.com
Lineage Therap Expands ATM Equity Offering Capacity - TipRanks
Lineage Cell Therapeutics files prospectus supplement for up to $60M ATM equity offering - TradingView
Lineage Cell Therapeutics (LCTX) files $100M shelf to issue shares, debt, warrants - Stock Titan
Lineage Cell (NYSE: LCTX) files supplement for $60M ATM shares - Stock Titan
Ligand Pharmaceuticals (LCTX) raises ATM ceiling to $60M with B. Riley - Stock Titan
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2025 earnings call transcript - MSN
US Market Wrap: Is Klotho Neurosciences Inc gaining market shareGap Down & Daily Technical Forecast Reports - baoquankhu1.vn
H.C. Wainwright Maintains Buy on Lineage Cell Therapeutics (LCTX) Mar 2026 - Meyka
Lineage Cell Therapeutics Extends Runway Amid R&D Surge - TipRanks
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2025 Earnings Call Transcript - Insider Monkey
Why Lineage Cell Therapeutics Inc. stock could outperform in 2026Portfolio Performance Summary & Free Verified High Yield Trade Plans - Naître et grandir
Regulatory Risks Loom for Lineage Cell Therapeutics as Legacy Pluripotent Cell Lines Face Potential Compliance Challenges - TipRanks
Can Lineage Cell Therapeutics Inc. stock resist market sell offsQuarterly Growth Report & Long Hold Capital Preservation Plans - Naître et grandir
Risk Off: Is Lineage Cell Therapeutics Inc stock overvalued or fairly pricedJuly 2025 Momentum & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Lineage Cell (LCTX) grants CFO 1.05M employee stock options - Stock Titan
Lineage Cell Therapeutics (LCTX) grants 900,000 stock options to General Counsel - Stock Titan
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target Raised to $3.00 - MarketBeat
LCTX Stock Rating Maintained as Buy; Price Target Raised by D. B - GuruFocus
H.C. Wainwright reiterates Buy on Lineage Cell stock, $9 target - Investing.com South Africa
Lineage Cell Therapeutics Inc Azioni (LCTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):